Can AI Design Therapies? (www.scmp.com)

ByteDance's drug development unit, Anew Therapeutics, showcased its AI-designed therapies at global conferences, highlighting its innovative approach to drug discovery. The unit operates internationally with bases in Shanghai, Singapore, and San Jose and boasts an impressive advisory board featuring notable figures from the biotech industry. During Immunology2026 in Boston, Chris Li, head of biology, presented a generative AI-designed treatment aimed at autoimmune diseases, illustrating the promising potential of AI in targeting complex medical conditions. The significance of Anew Therapeutics' advancements lies in its integration of AI into the drug discovery process, which could revolutionize how therapies are developed. Key technical contributions, such as AnewSampling—a framework designed to emulate molecular dynamics at an all-atom level—were set to be presented at the upcoming Free Energy Workshop in Barcelona. These efforts not only reflect the increasing intersection of AI and biotechnology but also pave the way for more efficient and precise therapies, potentially transforming healthcare outcomes in the future.